End‐of‐dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double‐blind study
Identifieur interne : 000406 ( France/Analysis ); précédent : 000405; suivant : 000407End‐of‐dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double‐blind study
Auteurs : Nicolas Simon [France] ; Joëlle Micallef [France] ; Jean-Charles Reynier [France] ; Monique Lesourd [France] ; Tatiana Witjas [France] ; André Alicherif [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-07.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Aged, Akinesia, Dopamine Agonists (blood), Dopamine Agonists (therapeutic use), Dose-Response Relationship, Drug, Double blind study, Drug Evaluation (methods), Female, Human, Humans, Infusions, Intravenous (methods), Intravenous administration, Male, Middle Aged, Nervous system diseases, Parkinson Disease (blood), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Pharmacodynamics, Pharmacokinetics, Piribedil, Piribedil (blood), Piribedil (therapeutic use), Retrospective Studies, Severity of Illness Index, Single dose, Time Factors, Treatment Outcome, akinesia, intravenous, pharmacokinetics/pharmacodynamics, piribedil, randomized double‐blind study.
- MESH :
- chemical , blood : Dopamine Agonists, Piribedil.
- chemical , therapeutic use : Dopamine Agonists, Piribedil.
- blood : Parkinson Disease.
- drug therapy : Parkinson Disease.
- methods : Drug Evaluation, Infusions, Intravenous.
- Aged, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Retrospective Studies, Severity of Illness Index, Time Factors, Treatment Outcome.
Abstract
This randomized, double‐blind trial was designed to define the possible relationship between piribedil plasma concentrations and the decrease of the Unified Parkinson's Disease Rating Scale (UPDRS) motor score or the switch from off to on state after single intravenous infusion. Ten fluctuating patients with idiopathic Parkinson's disease (PD) received escalating doses of piribedil (2–16 mg) and placebo. Starting from 2 mg, piribedil was effective in reducing the motor deficit (UPDRS, motor score) including akinesia at the first evaluation time point of 15 minutes, and in reversing off state of 7 of 10 patients. The doses were equally effective, although the effect was more sustained with the highest dose of 16 mg. Piribedil was well tolerated up to a 16‐mg dose and pharmacokinetics were linear up to the 16‐mg dose. Plasma levels of piribedil were not correlated to the motor score improvement or switch from off→on. In conclusion, a short single infusion of piribedil at 2 to 16 mg was safe and effective in improving motor symptoms, including akinesia, of fluctuating PD patients. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20400
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001885
- to stream Istex, to step Curation: 001885
- to stream Istex, to step Checkpoint: 002341
- to stream PubMed, to step Corpus: 003133
- to stream PubMed, to step Curation: 003133
- to stream PubMed, to step Checkpoint: 003143
- to stream Ncbi, to step Merge: 001168
- to stream Ncbi, to step Curation: 001168
- to stream Ncbi, to step Checkpoint: 001168
- to stream Main, to step Merge: 005018
- to stream PascalFrancis, to step Corpus: 001E31
- to stream PascalFrancis, to step Curation: 000E90
- to stream PascalFrancis, to step Checkpoint: 001E58
- to stream Main, to step Merge: 005336
- to stream Main, to step Curation: 003931
- to stream Main, to step Exploration: 003931
- to stream France, to step Extraction: 000406
Links to Exploration step
ISTEX:8D53D2A4341B0E12C30A815D20DEA8852D6955B3Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">End‐of‐dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double‐blind study</title><author><name sortKey="Simon, Nicolas" sort="Simon, Nicolas" uniqKey="Simon N" first="Nicolas" last="Simon">Nicolas Simon</name></author><author><name sortKey="Micallef, Joelle" sort="Micallef, Joelle" uniqKey="Micallef J" first="Joëlle" last="Micallef">Joëlle Micallef</name></author><author><name sortKey="Reynier, Jean Harles" sort="Reynier, Jean Harles" uniqKey="Reynier J" first="Jean-Charles" last="Reynier">Jean-Charles Reynier</name></author><author><name sortKey="Lesourd, Monique" sort="Lesourd, Monique" uniqKey="Lesourd M" first="Monique" last="Lesourd">Monique Lesourd</name></author><author><name sortKey="Witjas, Tatiana" sort="Witjas, Tatiana" uniqKey="Witjas T" first="Tatiana" last="Witjas">Tatiana Witjas</name></author><author><name sortKey="Alicherif, Andre" sort="Alicherif, Andre" uniqKey="Alicherif A" first="André" last="Alicherif">André Alicherif</name></author><author><name sortKey="Azulay, Jean Hilippe" sort="Azulay, Jean Hilippe" uniqKey="Azulay J" first="Jean-Philippe" last="Azulay">Jean-Philippe Azulay</name></author><author><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8D53D2A4341B0E12C30A815D20DEA8852D6955B3</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20400</idno><idno type="url">https://api.istex.fr/document/8D53D2A4341B0E12C30A815D20DEA8852D6955B3/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001885</idno><idno type="wicri:Area/Istex/Curation">001885</idno><idno type="wicri:Area/Istex/Checkpoint">002341</idno><idno type="wicri:doubleKey">0885-3185:2005:Simon N:end:of:dose</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15726579</idno><idno type="wicri:Area/PubMed/Corpus">003133</idno><idno type="wicri:Area/PubMed/Curation">003133</idno><idno type="wicri:Area/PubMed/Checkpoint">003143</idno><idno type="wicri:Area/Ncbi/Merge">001168</idno><idno type="wicri:Area/Ncbi/Curation">001168</idno><idno type="wicri:Area/Ncbi/Checkpoint">001168</idno><idno type="wicri:doubleKey">0885-3185:2005:Simon N:end:of:dose</idno><idno type="wicri:Area/Main/Merge">005018</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:05-0387232</idno><idno type="wicri:Area/PascalFrancis/Corpus">001E31</idno><idno type="wicri:Area/PascalFrancis/Curation">000E90</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001E58</idno><idno type="wicri:doubleKey">0885-3185:2005:Simon N:end:of:dose</idno><idno type="wicri:Area/Main/Merge">005336</idno><idno type="wicri:Area/Main/Curation">003931</idno><idno type="wicri:Area/Main/Exploration">003931</idno><idno type="wicri:Area/France/Extraction">000406</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">End‐of‐dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double‐blind study</title><author><name sortKey="Simon, Nicolas" sort="Simon, Nicolas" uniqKey="Simon N" first="Nicolas" last="Simon">Nicolas Simon</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Pharmacologie Medicale et Clinique, Centre Hospitalier Universitaire Timone, Marseille</wicri:regionArea><placeName><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Micallef, Joelle" sort="Micallef, Joelle" uniqKey="Micallef J" first="Joëlle" last="Micallef">Joëlle Micallef</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille</wicri:regionArea><placeName><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Reynier, Jean Harles" sort="Reynier, Jean Harles" uniqKey="Reynier J" first="Jean-Charles" last="Reynier">Jean-Charles Reynier</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille</wicri:regionArea><placeName><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Lesourd, Monique" sort="Lesourd, Monique" uniqKey="Lesourd M" first="Monique" last="Lesourd">Monique Lesourd</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherches Internationales Servier, Courbevoie</wicri:regionArea><wicri:noRegion>Courbevoie</wicri:noRegion><wicri:noRegion>Courbevoie</wicri:noRegion></affiliation></author><author><name sortKey="Witjas, Tatiana" sort="Witjas, Tatiana" uniqKey="Witjas T" first="Tatiana" last="Witjas">Tatiana Witjas</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille</wicri:regionArea><placeName><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Alicherif, Andre" sort="Alicherif, Andre" uniqKey="Alicherif A" first="André" last="Alicherif">André Alicherif</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille</wicri:regionArea><placeName><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Azulay, Jean Hilippe" sort="Azulay, Jean Hilippe" uniqKey="Azulay J" first="Jean-Philippe" last="Azulay">Jean-Philippe Azulay</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille</wicri:regionArea><placeName><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS‐Universite de la Mediterranee, Marseille</wicri:regionArea><placeName><settlement type="city">Marseille</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-07">2005-07</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="803">803</biblScope><biblScope unit="page" to="809">809</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">8D53D2A4341B0E12C30A815D20DEA8852D6955B3</idno><idno type="DOI">10.1002/mds.20400</idno><idno type="ArticleID">MDS20400</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Akinesia</term><term>Dopamine Agonists (blood)</term><term>Dopamine Agonists (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Double blind study</term><term>Drug Evaluation (methods)</term><term>Female</term><term>Human</term><term>Humans</term><term>Infusions, Intravenous (methods)</term><term>Intravenous administration</term><term>Male</term><term>Middle Aged</term><term>Nervous system diseases</term><term>Parkinson Disease (blood)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Pharmacodynamics</term><term>Pharmacokinetics</term><term>Piribedil</term><term>Piribedil (blood)</term><term>Piribedil (therapeutic use)</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Single dose</term><term>Time Factors</term><term>Treatment Outcome</term><term>akinesia</term><term>intravenous</term><term>pharmacokinetics/pharmacodynamics</term><term>piribedil</term><term>randomized double‐blind study</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Dopamine Agonists</term><term>Piribedil</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agonists</term><term>Piribedil</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Evaluation</term><term>Infusions, Intravenous</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Akinésie</term><term>Dose unique</term><term>Etude double insu</term><term>Homme</term><term>Parkinson maladie</term><term>Pharmacocinétique</term><term>Pharmacodynamie</term><term>Piribédil</term><term>Système nerveux pathologie</term><term>Voie intraveineuse</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This randomized, double‐blind trial was designed to define the possible relationship between piribedil plasma concentrations and the decrease of the Unified Parkinson's Disease Rating Scale (UPDRS) motor score or the switch from off to on state after single intravenous infusion. Ten fluctuating patients with idiopathic Parkinson's disease (PD) received escalating doses of piribedil (2–16 mg) and placebo. Starting from 2 mg, piribedil was effective in reducing the motor deficit (UPDRS, motor score) including akinesia at the first evaluation time point of 15 minutes, and in reversing off state of 7 of 10 patients. The doses were equally effective, although the effect was more sustained with the highest dose of 16 mg. Piribedil was well tolerated up to a 16‐mg dose and pharmacokinetics were linear up to the 16‐mg dose. Plasma levels of piribedil were not correlated to the motor score improvement or switch from off→on. In conclusion, a short single infusion of piribedil at 2 to 16 mg was safe and effective in improving motor symptoms, including akinesia, of fluctuating PD patients. © 2005 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>France</li></country><settlement><li>Marseille</li></settlement></list><tree><country name="France"><noRegion><name sortKey="Simon, Nicolas" sort="Simon, Nicolas" uniqKey="Simon N" first="Nicolas" last="Simon">Nicolas Simon</name></noRegion><name sortKey="Alicherif, Andre" sort="Alicherif, Andre" uniqKey="Alicherif A" first="André" last="Alicherif">André Alicherif</name><name sortKey="Azulay, Jean Hilippe" sort="Azulay, Jean Hilippe" uniqKey="Azulay J" first="Jean-Philippe" last="Azulay">Jean-Philippe Azulay</name><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name><name sortKey="Lesourd, Monique" sort="Lesourd, Monique" uniqKey="Lesourd M" first="Monique" last="Lesourd">Monique Lesourd</name><name sortKey="Micallef, Joelle" sort="Micallef, Joelle" uniqKey="Micallef J" first="Joëlle" last="Micallef">Joëlle Micallef</name><name sortKey="Reynier, Jean Harles" sort="Reynier, Jean Harles" uniqKey="Reynier J" first="Jean-Charles" last="Reynier">Jean-Charles Reynier</name><name sortKey="Witjas, Tatiana" sort="Witjas, Tatiana" uniqKey="Witjas T" first="Tatiana" last="Witjas">Tatiana Witjas</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000406 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000406 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:8D53D2A4341B0E12C30A815D20DEA8852D6955B3
|texte= End‐of‐dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double‐blind study
}}
| This area was generated with Dilib version V0.6.23. |  |